The original success of the copyright undeniably revolutionized the drug landscape, but betting in companies heavily reliant on unbranded versions presents a challenging picture. While early earnings were impressive, the end of patents and the emergence of less expensive alternatives have diminished market share. Therefore, a thorough analysis of c